Track topics on Twitter Track topics that are important to you
A round of Series B funding pulled in $45.7 million for Inflazome. -More-
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.
Roivant Sciences will use biologic drug candidate SAL200 are entering a global licensing agreement worth $667.5m with iNtRON Biotechnology. iNtRON...Read More... The post Deals this week: Roivant Scie...
Inflazome Ltd. (developing small-molecule therapies that block harmful inflammation) raised €40mm ($46mm) in its Series B financing led by Forbion, which was joined by other new backer Longitude Cap...
Utilizing the scientific expertise of our founders and advisors, Inflazome is leading the way in developing orally available drugs to address clinical unmet needs in inflammatory ...
We have published hundreds of Inflazome news stories on BioPortfolio along with dozens of Inflazome Clinical Trials and PubMed Articles about Inflazome for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Inflazome Companies in our database. You can also find out about relevant Inflazome Drugs and Medications on this site too.